Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3695-3703

  Touny, Lara H El ^a   Banerjee, Partha P ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; FULVESTRANT; GELATINASE B; GENISTEIN; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GROWTH REGULATION; HUMAN; HUMAN CELL; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTICARCINOGENIC AGENTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GENISTEIN; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; OSTEOPONTIN; PROSTATIC NEOPLASMS; UP-REGULATION;

EID: 65949113410     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2958     Document Type: Article

References (46)

1. Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med 2009; 60: 139-51.
2. Albertsen PC, Hartley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer, JAMA 2005; 293: 2095-101. (Pubitemid 40617061)
3. Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinegard D, Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma Clin. Exp Metastasis 2003; 20: 437-44. (Pubitemid 37108430)
4. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 1989; 9: 1291-9. (Pubitemid 19277158)
5. Craig AM, Bowden GT, Chambers AF. et al. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J. Cancer 1990; 46: 133-7. (Pubitemid 20225799)
6. Vanacker JM, Delmarre C, Guo X, Laudet V. Activation of the osteopontin promoter by the orphan nuclear receptor estrogen receptor related α. Cell Growth Differ 1998; 9: 1007-14. (Pubitemid 29036195)
7. Thalmann GM, Sikes RA, Devoll RE. et al. Osteopontin: Possible role in prostate cancer progression. Clin. Cancer Res 1999; 5: 2271-7. (Pubitemid 29399287)
8. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: Associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002; 95: 506-12.
9. Eorootan SS, Roster CS, Aachi VR. et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J. Cancer 2006; 118: 2255-61.
10. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007; 67: 330-40. (Pubitemid 46255790)
11. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. 3Genistein ehemoprevention: Timing and mechanisms of action in murine mammary and prostate. J. Nutr 2002; 132: 552-8S. (Pubitemid 34208769)
12. El Touny LH, Ranerjee PP. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype. Carcinogenesis 2007; 28: 1710-7. (Pubitemid 47289033)
13. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg MM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001; 61: 6777-82. (Pubitemid 32896500)
14. Chau MN, El Touny LH, Jagadeesh S, Ranerjee PP. Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3. Carcinogenesis 2007; 28: 2282-90. (Pubitemid 350111586)
15. Greenberg NM, DeMayo F, Finegold ML et al. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U S A 1995; 92: 3439-43.
16. El Touny LH, Banerjee PP. Genistein induces the metastasis suppressor kangai-1 which mediates its antiinvasive effects in TRAMP cancer cells. Biochem Biophys Res Commun 2007; 361: 169-75.
17. Desai R, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol. Cancer 2007; 6: 18. (Pubitemid 46443394)
18. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J. Nutr 2005; 135: 989-95. (Pubitemid 40638296)
19. El-Tanani MK, Campbell EC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006; 17: 463-74.
20. Vatanparast H, Chilibeck PD. Does the effect of soy phytoestrogens on bone in postmenopausal women depend on the equol-producing phenotype? Nutr Rev 2007; 65: 294-9.
21. Limer JL, Parkes AT, Speirs V. Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro. Int J. Cancer 2006; 119: 515-21. (Pubitemid 43955703)
22. Wietrzyk J, Mazurkiewiez M, Madej J. et al. Genistein alone or combined with cyclophosphamide may stimulate 16/C transplantable mouse mammary cancer growth. Med Sci Monit 2004; 10: BR414-9. (Pubitemid 39546029)
23. Moore AB, Castro L, Yu L. et al. Stimulatory and inhibitory effects of genistein on human uterine leiomyoma cell proliferation are influenced by the concentration. Hum Reprod 2007; 22: 2623-31. (Pubitemid 47434204)
24. Cooper CR, Pienta KJ. Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis 2000; 3: 6-12. (Pubitemid 30616513)
25. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994; 264: 569-71. (Pubitemid 24185862)
26. Kaplan-Lefko PJ, Chen TM, Ittmann MM. et al. Pathoblology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003; 55: 219-37. (Pubitemid 36532401)
27. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H, Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl. Acad. Sci. U S A 2001; 98: 10350-5. (Pubitemid 32803023)
28. Tuck AB, O'Malley FP, Singhal H. et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997; 121: 578-84.
29. Kolb A, Kleeff J, Guweidhi A. et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol. Ther. 2005; 4: 740-6. (Pubitemid 41351173)
30. Shimada Y, Watanabe G, Kawamura J. et al. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor inarkers. Oncology 2005: 68: 285-92. (Pubitemid 41158988)
31. Hu Z, Lin D, Yuan J. et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin. Cancer Res 2005; 11: 4646-52. (Pubitemid 41557181)
32. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF. Reduced malignancy of ras-transformed NTH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 1994; 54: 832-7. (Pubitemid 24068345)
33. Frey AB, Wall A, Pass H, Lonardo F. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma Histopathology 2007; 50: 720-6.
34. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor inducing kinase: A key regulator in osteopontin-induced MAPK/IκB kinase dependent NF-κB-mediated promatrix met al.loproteinase-9 activation. Glycoconj J. 2006; 23: 221-32. (Pubitemid 43725201)
35. Zirngibl RA, Chan JS, Aubin JE. Estrogen receptorrelated receptor α (ERRα) regulates osteopontin expression through a non-canonical ERRα response element in a cell context-dependent manner. J. Mol. Endocrinol. 2008; 40: 61-73.
36. Craig AM, Denhardt DT. The murine gene encoding secreted phosphoprotein 1 (osteopontin) : promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene 1991; 100: 163-71.
37. Shao J, Washington MK, Saxena R, Sheng H. Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin. Carcinogenesis 2007; 28: 2476-83. (Pubitemid 350238949)
38. Seo HS, DeNardo DG, Jacquot Y. et al. Stimulatory effect of genistein and apigenin on the growth of breast, cancer cells correlates with their ability to activate ERα, Breast Cancer Res Treat 2006; 99: 121-34. (Pubitemid 44268260)
39. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER) -α and ER-β in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000; 60: 3175-82. (Pubitemid 30407914)
40. Lakshman M, Xu L, Ananthanarayanan V. et al. Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 2008; 68: 2024-32.
41. Hillman GG, Wang Y, Kucuk O. et al. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol. Cancer Ther. 2004; 3: 1271-9. (Pubitemid 39440172)
42. Li Y, Sarkar FH. Inhibition of nuclear factor kB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res 2002; 8: 2369-77. (Pubitemid 34753612)
43. Grossini E, Molinari C, Mary DA. et al. Intracoronary genistein acutely increases coronary blood flow in anesthetized pigs through β-adrenergic mediated nitric oxide release and estrogenic receptors. Endocrinology 2008; 149: 2678-87.
44. Kousidou OC, Mitropoulou TN, Roussidis AE, Kletsas D, Theocharis AD, Karamanos NK, Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of met al.loproteinases and their tissue inhibitors. Int J. Oncol 2005; 26: 1101-9.
45. Chiaverotti T, Couto SS, Donjacour A. et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J. Pathol 2008; 172: 236-46.
46. Huss WJ, Gray DR, Tavakoli K. et al. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007; 9: 938-50. (Pubitemid 350086439)